Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 2
2006 2
2007 2
2008 1
2009 2
2010 11
2011 8
2012 7
2013 7
2014 3
2015 6
2016 9
2017 8
2018 4
2019 5
2020 1
2021 5
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Sobas M, et al. Among authors: legros l. Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201. Blood Adv. 2022. PMID: 35802458 Free PMC article.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: legros l. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission.
Dulucq S, Hayette S, Cayuela JM, Bauduer F, Chabane K, Chevallier P, Cony-Makhoul P, Flandrin-Gresta P, Jeune CL, Bris YL, Legros L, Maisonneuve H, Roy L, Mahon FX, Sloma I, Rea D, Nicolini FE. Dulucq S, et al. Among authors: legros l. Haematologica. 2022 Dec 1;107(12):2944-2949. doi: 10.3324/haematol.2022.280740. Haematologica. 2022. PMID: 35924576 Free PMC article. No abstract available.
Imatinib treatment and Aβ42 in humans.
Olsson B, Legros L, Guilhot F, Strömberg K, Smith J, Livesey FJ, Wilson DH, Zetterberg H, Blennow K. Olsson B, et al. Among authors: legros l. Alzheimers Dement. 2014 Oct;10(5 Suppl):S374-80. doi: 10.1016/j.jalz.2013.08.283. Epub 2013 Dec 10. Alzheimers Dement. 2014. PMID: 24331439
Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples.
Oueslati S, Manai Bouokazi M, Ramdhani I, Escaut L, Pham T, Ouzani S, Anguel N, Bulifon S, Vauloup-Fellous C, Coilly A, Legros L, Guichardon M, Fortineau N, Dortet L, Roque-Afonso AM, Naas T. Oueslati S, et al. Among authors: legros l. Diagnostics (Basel). 2022 Oct 7;12(10):2427. doi: 10.3390/diagnostics12102427. Diagnostics (Basel). 2022. PMID: 36292116 Free PMC article.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group. Guilhot F, et al. Among authors: legros l. Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. doi: 10.1053/shem.2003.50048. Semin Hematol. 2003. PMID: 12783382 Review.
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, Cony-Makhoul P, Coiteux V, Sutton L, Abarah W, Pouaty C, Pignon JM, Choufi B, Visanica S, Deau B, Morisset L, Cayssials E, Molimard M, Bouchet S, Mahon FX, Nicolini F, Aegerter P, Cayuela JM, Delord M, Bruzzoni-Giovanelli H, Rousselot P; Groupe Français pour la LMC (Fi-LMC). Johnson-Ansah H, et al. Among authors: legros l. Pharmaceutics. 2022 Aug 12;14(8):1676. doi: 10.3390/pharmaceutics14081676. Pharmaceutics. 2022. PMID: 36015302 Free PMC article.
84 results